Kezar Life Sciences Statistics
Share Statistics
Kezar Life Sciences has 7.30M shares outstanding. The number of shares has increased by 0.37% in one year.
| Shares Outstanding | 7.30M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.22% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 6.21M |
| Failed to Deliver (FTD) Shares | 116.88K |
| FTD / Avg. Volume | 110.07% |
Short Selling Information
The latest short interest is 177.96K, so 2.44% of the outstanding shares have been sold short.
| Short Interest | 177.96K |
| Short % of Shares Out | 2.44% |
| Short % of Float | 2.87% |
| Short Ratio (days to cover) | 0.93 |
Valuation Ratios
The PE ratio is -6.74 and the forward PE ratio is -0.72.
| PE Ratio | -6.74 |
| Forward PE | -0.72 |
| PS Ratio | 98.15 |
| Forward PS | 14.8 |
| PB Ratio | 3.66 |
| P/FCF Ratio | -8.23 |
| PEG Ratio | n/a |
Enterprise Valuation
Kezar Life Sciences Inc. has an Enterprise Value (EV) of 87.67M.
| EV / Earnings | -0.86 |
| EV / Sales | 12.52 |
| EV / EBITDA | -0.88 |
| EV / EBIT | -0.83 |
| EV / FCF | -1.05 |
Financial Position
The company has a current ratio of 11.66, with a Debt / Equity ratio of 0.07.
| Current Ratio | 11.66 |
| Quick Ratio | 11.66 |
| Debt / Equity | 0.07 |
| Total Debt / Capitalization | 6.52 |
| Cash Flow / Debt | -6.24 |
| Interest Coverage | -67.89 |
Financial Efficiency
Return on equity (ROE) is -0.54% and return on capital (ROIC) is -50.96%.
| Return on Equity (ROE) | -0.54% |
| Return on Assets (ROA) | -0.46% |
| Return on Capital (ROIC) | -50.96% |
| Revenue Per Employee | 120.69K |
| Profits Per Employee | -1.76M |
| Employee Count | 58 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -19.47% in the last 52 weeks. The beta is 0.22, so Kezar Life Sciences 's price volatility has been higher than the market average.
| Beta | 0.22 |
| 52-Week Price Change | -19.47% |
| 50-Day Moving Average | 35.47 |
| 200-Day Moving Average | 14.99 |
| Relative Strength Index (RSI) | 23.64 |
| Average Volume (20 Days) | 106.19K |
Income Statement
In the last 12 months, Kezar Life Sciences had revenue of $7.00M and earned -$101.87M in profits. Earnings per share was $-1.4.
| Revenue | 7.00M |
| Gross Profit | 5.93M |
| Operating Income | -105.24M |
| Net Income | -101.87M |
| EBITDA | -99.25M |
| EBIT | -105.24M |
| Earnings Per Share (EPS) | -1.4 |
Balance Sheet
The company has $35.49M in cash and $18.93M in debt, giving a net cash position of $16.56M.
| Cash & Cash Equivalents | 35.49M |
| Total Debt | 18.93M |
| Net Cash | 16.56M |
| Retained Earnings | -350.76M |
| Total Assets | 164.09M |
| Working Capital | 135.95M |
Cash Flow
In the last 12 months, operating cash flow was -$81.64M and capital expenditures -$1.81M, giving a free cash flow of -$83.45M.
| Operating Cash Flow | -81.64M |
| Capital Expenditures | -1.81M |
| Free Cash Flow | -83.45M |
| FCF Per Share | -1.15 |
Margins
Gross margin is 84.77%, with operating and profit margins of -1.50K% and -1.46K%.
| Gross Margin | 84.77% |
| Operating Margin | -1.50K% |
| Pretax Margin | -1.46K% |
| Profit Margin | -1.46K% |
| EBITDA Margin | -1.42K% |
| EBIT Margin | -1.50K% |
| FCF Margin | -1.19K% |
Dividends & Yields
KZR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -20.77% |
| FCF Yield | -169.7% |
Analyst Forecast
The average price target for KZR is $11, which is 63.2% higher than the current price. The consensus rating is "Hold".
| Price Target | $11 |
| Price Target Difference | 63.2% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Oct 30, 2024. It was a backward split with a ratio of 1:10.
| Last Split Date | Oct 30, 2024 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -3.45 |
| Piotroski F-Score | 2 |